20 results
Thumbnail

- D3.196 - Efficacy of sublingual immunotherapy in children with allergic rhinitis

Thumbnail

D3.193 - Impact of subcutaneous allergen immunotherapy on autoimmune disease development or exacerbations: a cross-sectional study

Thumbnail

D3.194 - Renewal’s analysis of liquid sublingual immunotherapy (SLIT) treatments using iPUMP: SPEED study, a Real-Life study

Thumbnail

D3.195 - Reasons for declining venom immunotherapy and its burden on patients' daily lives

Thumbnail

D3.197 - When is molecular testing necessary? Rethinking allergy diagnostics for Dermatophagoides pteronyssinus

Thumbnail

D3.198 - Hymenoptera Venom Allergy: A Case Report on Safe Discontinuation After Five Years of Venom Immunotherapy

Thumbnail

D3.202 - Allergen-Specific Immunotherapy Is Still Rarely Used: Results of an Online Survey in Lithuania

Thumbnail

D3.203 - Yeast surface display as platform for generation of nanobodies to single allergens and allergen extracts

Thumbnail

D3.204 - Elevated Tryptase Levels in a Severe Asthmatic Patient Undergoing SCIT for Birch: Implications for Monitoring and Personalized Treatment

Thumbnail

D3.205 - Online Education Increases Clinician Knowledge and Confidence in Utilizing Allergen Immunotherapy for Respiratory Allergic Disease

Thumbnail

D1.370 - Clinical outcomes and quality of life improvement in children with moderate-to-severe atopic dermatitis and atopic multimorbidity treated with dupilumab

Thumbnail

D1.362 - Exploratory Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of YH35324, a Long-Acting high-affinity IgETrap-Fc protein, in Patients with Chronic Spontaneous Urticaria Refractory to Omalizumab

Thumbnail

D1.363 - Efficacy and safety of Mepolizumab in treatment of eosinophilic granulomatosis with polyangiitis

Thumbnail

D1.364 - Update on the Observed incidence of Anaphylaxis and Serum Sickness in Patients Receiving Omalizumab in a Canadian Tertiary Allergy/Asthma Clinic

Thumbnail

D1.365 - ZL-1503: A Bispecific Antibody Targeting Inflammatory and Pruritogenic Pathways with a Prolonged Serum Half-life and Sustained Activity in Non-human Primates

Thumbnail

D1.366 - Improvement Over Time in Specific Aspects of Quality of Life in Patients with Chronic Spontaneous Urticaria Treated with Omalizumab

Thumbnail

D1.367 - Dupilumab for refractory pruritus in hematological and non-hematological malignancies – preliminary results

Thumbnail

D1.368 - Anti-interleukin-5 treatment in patients with severe eosinophilic asthma provides consistent symptom control for at least 8 years

Thumbnail

D1.369 - Characteristics of patients with severe asthma undergoing biological treatment at a reference center

Thumbnail

D1.371 - Dupilumab for the treatment of refractory severe chronic spontaneous urticaria